Prospective, multi-center post-marketing surveillance cohort study to monitor the safety of the human papillomavirus-16/18 AS04-adjuvanted vaccine in Chinese girls and women aged 9 to 45 years, 2018-2020

• मुख्य लेखकों: Qianhui Wu (लेखक), Mengcen Qian (लेखक), Sarah Welby (लेखक), Adrienne Guignard (लेखक), Dominique Rosillon (लेखक), Kusuma Gopala (लेखक), Yuan Xu (लेखक), Keruo Liu (लेखक), Yunkun He (लेखक), Ning Jiang (लेखक), Qin Tan (लेखक), Jiamin Xie (लेखक), Taoying Zhu (लेखक), Qizhang Wang (लेखक), Yingzi Pan (लेखक), Ruikun Zeng (लेखक), Jie Yang (लेखक), Xiaoqian Zhao (लेखक), Man Zhou (लेखक), Adoración Navarro-Torné (लेखक), Hongjie Yu (लेखक), Dorota Borys (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Taylor & Francis Group, 2023-12-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

ABSTRACTFollowing the approval of Cervarix for the immunization of girls and women in China against high-risk human papillomavirus types 16 and 18, a non-interventional post-authorization safety study was performed. A multi-center prospective cohort study assessed safety following Cervarix vaccinati...